8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): July 25, 2013

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-1136	22-0790350
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

345 Park Avenue

New York, NY, 10154

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On July 25, 2013, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the second quarter of 2013. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1	Press release of Bristol-Myers Squibb Company dated July 25, 2013.
99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRISTOL-MYERS SQUIBB COMPANY
Dated: July 25, 2013	By:	/s/ Sandra Leung
	Name:	Sandra Leung
	Title:	General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release of Bristol-Myers Squibb Company dated July 25, 2013.
99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

EX-99.1

Exhibit 99.1

Bristol-Myers Squibb Reports Second Quarter 2013 Financial Results

• Posts Second Quarter GAAP EPS of $0.32 and non-GAAP EPS of $0.44

• Presents Important New Clinical Data for Immuno-Oncology, Cardiovascular and Immunoscience Franchises

• Resubmits Forxiga^® in U.S. for the Treatment of Type 2 Diabetes and Completes Regulatory Filing in U.S. for Eliquis^® for the Prevention of DVT After Hip or Knee Replacement Surgery and Metreleptin for the Treatment of Metabolic Disorders Associated with Lipodystrophy

• Adjusts 2013 GAAP EPS Guidance Range to $1.41 to $1.49 and non-GAAP EPS Guidance Range to $1.70 to $1.78

(NEW YORK, July 25, 2013) – Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the second quarter of 2013 highlighted by the resubmission of Forxiga in the U.S., the completion of regulatory filings for Eliquis and Metreleptin in the U.S., and the presentation of important data from its immuno-oncology franchise at ASCO, for Orencia^® at EULAR and for Eliquis at ISTH. In addition, the company adjusted GAAP EPS and non-GAAP EPS guidance for 2013.

“In the second quarter, the strength in the performance of some of our key products, the important data we presented across our portfolio and the key regulatory filings we made in the U.S. strengthen our confidence as we build a solid foundation for future growth,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We will continue to invest the necessary resources across our portfolio to grow existing brands, support the execution of new launches and deliver a diverse and sustainable pipeline,” Andreotti said.

	Second Quarter
$ amounts in millions, except per share amounts	2013		2012		Change
Net Sales	$	4,048	$	4,443		(9	)%
GAAP Diluted EPS		0.32		0.38		(16	)%
Non-GAAP Diluted EPS		0.44		0.48		(8	)%

SECOND QUARTER FINANCIAL RESULTS

• Bristol-Myers Squibb posted second quarter 2013 net sales of $4.0 billion, a decrease of 9% compared to the same period a year ago, following the U.S. patent expiration of Avapro^®/Avalide^® in March 2012 and Plavix^® in May 2012. Excluding Plavix and Avapro/Avalide, net sales grew by 10% compared to the second quarter of 2012.

• U.S. net sales decreased 22% to $2.0 billion in the quarter compared to the same period a year ago. International net sales increased 10% to $2.0 billion.

• Gross margin as a percentage of net sales was 72.6% in the quarter compared to 72.0% in the same period a year ago.

• Marketing, selling and administrative expenses increased 4% to $1.0 billion in the quarter.

• Advertising and product promotion spending decreased 3% to $218 million in the quarter.

• Research and development expenses decreased 1% to $951 million in the quarter.

• The effective tax rate on earnings before income taxes was 0% in the quarter, compared to 23.7% in the second quarter last year. Income taxes in the current quarter reflect a more favorable earnings mix between high and low tax jurisdictions primarily, driven by specified items.

• The company reported net earnings attributable to Bristol-Myers Squibb of $536 million, or $0.32 per share, in the quarter compared to $645 million, or $0.38 per share, a year ago.

• The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $730 million, or $0.44 per share, in the second quarter, compared to $808 million, or $0.48 per share, for the same period in 2012. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.

• Cash, cash equivalents and marketable securities were $6.0 billion, with a net debt position of $1.2 billion, as of June 30, 2013.

SECOND QUARTER PRODUCT AND PIPELINE UPDATE

Bristol-Myers Squibb’s global sales in the second quarter included Yervoy^®, which grew 44%, Onglyza^®/Kombiglyze^™ , which grew 40%, Sprycel^®, which grew 28%, and Orencia, which grew 21%.

Orencia

• In June, Japan’s Ministry of Health, Labour and Welfare approved the subcutaneous formulation of Orencia for the treatment of rheumatoid arthritis in cases where existing treatments are inadequate. The company co-develops and co-commercializes Orencia in Japan with Ono Pharmaceutical Co., Ltd.

• In June, at the European League Against Rheumatism annual congress in Madrid, the company presented year two data from the head-to-head AMPLE study that showed the subcutaneous formulation of Orencia achieved comparable rates of efficacy and similar onset of response versus Humira^® among biologic-naïve patients with moderate to severe rheumatoid arthritis. Overall safety data were similar for both groups while discontinuations due to adverse events were higher for Humira.

Eliquis

• In July, the U.S. Food and Drug Administration (FDA) accepted for review the Supplemental New Drug Application for Eliquis, for the prevention of deep vein thrombosis following hip or knee replacement surgery. The Prescription Drug User Fee Act (PDUFA) date—the date by which a decision by the FDA is expected—is March 15, 2014.

• In June, the company and its partner, Pfizer, announced that results from the Phase III AMPLIFY trial, which evaluated Eliquis versus the current standard of care for the treatment of acute venous thromboembolism, were published online by the New England Journal of Medicine and presented at the International Society on Thrombosis and Haemostasis congress in Amsterdam. The results showed that Eliquis demonstrated comparable efficacy and significantly lower rates of major bleeding compared to the current standard of care.

• In May, the company and its partner, Pfizer, announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, a peer-reviewed journal of the American Heart Association. The trends across the subgroup analysis were consistent with the overall study results that demonstrated Eliquis’ superiority versus warfarin in the reduction of stroke or systemic embolism and the number of major bleeding events and mortality in patients with nonvalvular atrial fibrillation.

Forxiga

• The company and its partner AstraZeneca resubmitted to the FDA the New Drug Application for Forxiga for the treatment of adults with type 2 diabetes. The resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years’ duration) from previously submitted studies.

• In June, at the American Diabetes Association scientific sessions in Chicago, the company and its partner, AstraZeneca, presented results from a two-week Phase IIa pilot study evaluating Forxiga added to insulin in 70 adult patients with sub-optimally controlled type 1 diabetes that showed that mean daily blood glucose derived from 7-point glucose measurements trended downward in all treatment groups through day seven and that reductions in total daily insulin dosing at day seven were observed with Forxiga.

Onglyza^®

• In June, the company and its partner, AstraZeneca, announced top-line results from the Phase IV SAVOR-TIMI-53 trial in adult patients with type 2 diabetes and either a history of established cardiovascular disease or multiple risk factors that showed Onglyza met its primary safety objective of non-inferiority and did not meet the primary efficacy objective of superiority, for a composite endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke, versus placebo when added to the current standard of care. The results will be presented at the European Society of Cardiology meeting in September.

Metreleptin

• In June, the FDA accepted the filing and granted a Priority Review designation, for metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy, a rare disease estimated to affect a few thousand people around the world, often with an early age of onset. In July, the FDA notified the company and its partner, AstraZeneca, that it will require a three-month extension to complete its review of the data supporting the application. The PDUFA date is February 27, 2014.

Nivolumab

• In June, at the annual meeting of the American Society of Clinical Oncology in Chicago, the company announced the results from a dose-ranging Phase I trial evaluating the safety and anti-tumor activity of nivolumab combined either concurrently or sequentially with Yervoy in patients with advanced melanoma. In patients who received the 1 mg/kg nivolumab + 3 mg/kg Yervoy doses in the concurrent regimen, 53% (n= 9 of 17) had confirmed objective responses based on modified World Health Organization criteria. In all nine of the responders, tumors shrank by at least 80% by the time of the first scheduled clinical treatment assessment (12 weeks), including three complete responses. The data were also published in the New England Journal of Medicine.

Elotuzumab

• In June, at the European Hematology Association annual congress in Stockholm, the company and its partner, AbbVie, presented updated efficacy and safety data from a small, randomized, Phase II open-label study of patients with previously-treated multiple myeloma that demonstrated median progression-free survival of 33 months and an objective response rate of 92% among patients treated with the investigational monoclonal antibody elotuzumab 10 mg/kg in combination with lenalidomide and low-dose dexamethasone.

SECOND QUARTER BUSINESS DEVELOPMENT UPDATE

• In June, the company and Simcere Pharmaceutical Group announced the companies agreed to collaborate in China on the development and commercialization of the subcutaneous formulation of Orencia for the treatment of rheumatoid arthritis.

2013 FINANCIAL GUIDANCE

Bristol-Myers Squibb is adjusting its 2013 GAAP EPS guidance range to $1.41 to $1.49, from $1.54 to $1.64, and its non-GAAP EPS guidance range to $1.70 to $1.78, from $1.78 to $1.88. Both GAAP and non-GAAP guidance assume current exchange rates. Key 2013 non-GAAP guidance assumptions include:

• Worldwide sales between $16.0 billion and $16.5 billion.

• Full-year gross margin as a percentage of sales of approximately 73%.

• Advertising and promotion expense increasing in the mid-single digit range.

• Marketing, sales and administrative expenses remaining flat versus last year.

• Research and development expenses growing in the low-single-digit range.

• An effective tax rate of approximately 15%.

The financial guidance for 2013 excludes the impact of any potential strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2013 guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.

Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related earnings per share information. These measures are adjusted to exclude certain costs, expenses, significant gains and losses and other specified items. Among the items in GAAP measures but excluded for purposes of determining adjusted earnings and other adjusted measures are: restructuring and other exit costs; accelerated depreciation charges; IPRD and asset impairments; charges and recoveries relating to significant legal proceedings; upfront, milestone and other licensing payments for in-licensing of products that have not achieved regulatory approval which are immediately expensed; net amortization of acquired intangible assets and deferred income related to Amylin; pension settlement charges; and significant tax events. This information is intended to enhance an investor’s overall understanding of the company’s past financial performance and prospects for the future. Non-GAAP financial measures provide the company and its investors with an indication of the company’s baseline performance before items that are considered by the company not to be reflective of the company’s ongoing results. The company uses non-GAAP gross profit, non-GAAP marketing, selling and administrative expense, non-GAAP research and development expense, and non-GAAP other income and expense measures to set internal budgets, manage costs, allocate resources, and plan and forecast future periods. Non-GAAP effective tax rate measures are primarily used to plan and forecast future periods. Non-GAAP earnings and earnings per share measures are primary indicators the company uses as a basis for evaluating company performance, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as “anticipate”, “estimates”, “should”, “expect”, “guidance”, “project”, “intend”, “plan”, “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to execute successfully its strategic plans, including its String of Pearls strategy, the expiration of patents or data protection on certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company and Conference Call Information

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

There will be a conference call on July 25, 2013, at 10:30 a.m. ET during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live web cast of the call at http://investor.bms.com or by dialing: 913-981-5537, confirmation code: 5748907. Materials related to the call will be available at the same website prior to the call.

For more information, contact: Jennifer Fron Mauer, 609-252-6579, jennifer.mauer@bms.com, Communications; John Elicker, 609-252-4611, john.elicker@bms.com, Ranya Dajani, 609-252-5330, ranya.dajani@bms.com, or Ryan Asay, 609-252-5020, ryan.asay@bms.com, Investor Relations.

Abilify^® is a trademark of Otsuka Pharmaceutical Co., Ltd.

Atripla^® is a trademark of Bristol-Myers Squibb Co. and Gilead Sciences, Inc.

Avapro^® , Avalide^®, and Plavix^® are trademarks of Sanofi.

Byetta^® and Bydureon^® are trademarks of Amylin Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals LP.

Erbitux^® is a trademark of ImClone LLC. ImClone Systems is a wholly-owned subsidiary of Eli Lilly and Company.

Humira^® is a trademark of AbbVie Biotechnology LTD.

All other brand names are registered trademarks of the company and/or one of its subsidiaries.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED PRODUCTS

FOR THE THREE MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, dollars in millions)

The following table sets forth worldwide and U.S. reported net sales for selected products. In addition, the table includes, where applicable, the estimated total U.S. prescription change for the retail and mail-order channels for the comparative periods presented for certain of the company’s U.S. pharmaceutical products based on third-party data. A significant portion of the company’s U.S. pharmaceutical sales is made to wholesalers. Where changes in reported net sales differ from prescription growth, this change in net sales may not reflect underlying prescriber demand.

	Worldwide Net Sales						U.S. Net Sales
	2013		2012		% Change		2013		2012		% Change		% Change in U.S. Total Prescriptions vs. 2012
Three Months Ended June 30,
Key Products
Virology
Baraclude	$	371	$	357		4%	$	73	$	59		24%		4%
Reyataz		431		406		6%		200		199		1%		(6)%
Sustiva Franchise		411		388		6%		275		259		6%		(2)%
Oncology
Erbitux		171		179		(4)%		168		176		(5)%		N/A
Sprycel		312		244		28%		135		91		48%		23%
Yervoy		233		162		44%		140		122		15%		N/A
Neuroscience
Abilify		563		711		(21)%		378		533		(29)%		—
Metabolics
Bydureon		66		—		N/A		57		—		N/A		N/A
Byetta		104		—		N/A		74		—		N/A		N/A
Forxiga		5		N/A		N/A		N/A		N/A		N/A		N/A
Onglyza/Kombiglyze		240		172		40%		167		126		33%		1%
Immunoscience
Nulojix		6		3		100%		4		2		100%		N/A
Orencia		352		290		21%		238		199		20%		N/A
Cardiovascular
Avapro/Avalide		56		117		(52)%		(9)		22		**		N/A
Eliquis		12		1		**		5		—		N/A		N/A
Plavix		44		741		(94)%		18		713		(97)%		N/A
Mature Products and All Other		671		672		—		122		128		(5)%		N/A
Total		4,048		4,443		(9)%		2,045		2,629		(22)%		N/A

** In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

SELECTED PRODUCTS

FOR THE SIX MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, dollars in millions)

The following table sets forth worldwide and U.S. reported net sales for selected products. In addition, the table includes, where applicable, the estimated total U.S. prescription change for the retail and mail-order channels for the comparative periods presented for certain of the company’s U.S. pharmaceutical products based on third-party data. A significant portion of the company’s U.S. pharmaceutical sales is made to wholesalers. Where changes in reported net sales differ from prescription growth, this change in net sales may not reflect underlying prescriber demand.

	Worldwide Net Sales						U.S. Net Sales
	2013		2012		% Change		2013			2012		% Change		% Change in U.S. Total Prescriptions vs. 2012
Six Months Ended June 30,
Key Products
Virology
Baraclude	$	737	$	682		8%	$	141		$	115		23%		5%
Reyataz		792		764		4%		393			387		2%		(7)%
Sustiva Franchise		798		774		3%		526			513		3%		(3)%
Oncology
Erbitux		333		358		(7)%		326			352		(7)%		N/A
Sprycel		599		475		26%		250			186		34%		20%
Yervoy		462		316		46%		299			239		25%		N/A
Neuroscience
Abilify		1,085		1,332		(19)%		706			978		(28)%		(1)%
Metabolics
Bydureon		118		—		N/A		109			—		N/A		N/A
Byetta		189		—		N/A		158			—		N/A		N/A
Forxiga		8		N/A		N/A		N/A			N/A		N/A		N/A
Onglyza/Kombiglyze		442		333		33%		307			246		25%		4%
Immunoscience
Nulojix		11		4		**		8			3		**		N/A
Orencia		672		544		24%		452			370		22%		N/A
Cardiovascular
Avapro/Avalide		102		324		(69)%		(9	)		130		**		N/A
Eliquis		34		1		**		22			—		N/A		N/A
Plavix		135		2,434		(94)%		84			2,361		(96)%		N/A
Mature Products and All Other		1,362		1,353		1%		244			250		(2)%		N/A
Total		7,879		9,694		(19)%		4,016			6,130		(34)%		N/A

** In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, amounts in millions except per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Net Sales	$	4,048		$	4,443		$	7,879		$	9,694
Cost of products sold		1,108			1,245			2,171			2,548
Marketing, selling and administrative		1,042			1,004			2,036			2,006
Advertising and product promotion		218			224			407			418
Research and development		951			962			1,881			1,871
Other (income)/expense		199			(51	)		180			(235	)
Total expenses		3,518			3,384			6,675			6,608
Earnings Before Income Taxes		530			1,059			1,204			3,086
Provision for income taxes		—			251			51			796
Net Earnings		530			808			1,153			2,290
Net Earnings/(Loss) Attributable to Noncontrolling Interest		(6	)		163			8			544
Net Earnings Attributable to BMS	$	536		$	645		$	1,145		$	1,746
Earnings per Common Share
Basic	$	0.33		$	0.38		$	0.70		$	1.04
Diluted	$	0.32		$	0.38		$	0.69		$	1.02
Average Common Shares Outstanding:
Basic		1,644			1,683			1,641			1,685
Diluted		1,660			1,701			1,658			1,704
Other (income)/expense
Interest expense	$	50		$	41		$	100		$	83
Investment income		(28	)		(22	)		(53	)		(58	)
Provision for restructuring		173			20			206			42
Litigation charges/(recoveries)		(22	)		22			(22	)		(150	)
Equity in net income of affiliates		(50	)		(53	)		(86	)		(110	)
Out-licensed intangible asset impairment		—			—			—			38
Gain on sale of product lines, businesses and assets		—			(3	)		(1	)		(3	)
Other income received from alliance partners, net		(32	)		(83	)		(89	)		(129	)
Pension settlements		101			—			101			—
Other		7			27			24			52
Other (income)/expense	$	199		$	(51	)	$	180		$	(235	)

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, dollars in millions)

	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Accelerated depreciation, asset impairment and other shutdown costs	$	—		$	147		$	—		$	147
Amortization of acquired Amylin intangible assets		137			—			275			—
Amortization of Amylin collaboration proceeds		(67	)		—			(134	)		—
Amortization of Amylin inventory adjustment		—			—			14			—
Cost of products sold		70			147			155			147
Marketing, selling and administrative*		1			5			2			13
Research and development**		—			45			—			103
Provision for restructuring		173			20			206			42
Acquisition and collaboration related items		(10	)		1			(10	)		13
Litigation charges/(recoveries)		(23	)		22			(23	)		(150	)
Out-licensed intangible asset impairment		—			—			—			38
Loss on debt repurchase		—			—			—			19
Upfront, milestone and other licensing receipts		—			—			(14	)		—
Pension settlements		99			—			99			—
Other (income)/expense		239			43			258			(38	)
Increase to pretax income		310			240			415			225
Income tax on items above		(116	)		(77	)		(151	)		(69	)
Increase to net earnings	$	194		$	163		$	264		$	156

* Specified items in marketing, selling and administrative are process standardization implementation costs.

** Specified items in research and development in 2012 are IPRD impairment charges.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO GAAP LINE ITEMS

FOR THE THREE MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, dollars in millions)

Three months ended June 30, 2013	GAAP		Specified Items*		Non GAAP
Gross Profit	$	2,940		70	$	3,010
Marketing, selling and administrative		1,042		(1)		1,041
Research and development		951		—		951
Other (income)/expense		199		(239)		(40)
Effective Tax Rate		—		13.8%		13.8%
Three months ended June 30, 2012	GAAP		Specified Items*		Non GAAP
Gross Profit	$	3,198		147	$	3,345
Marketing, selling and administrative		1,004		(5)		999
Research and development		962		(45)		917
Other (income)/expense		(51)		(43)		(94)
Effective Tax Rate		23.7%		1.6%		25.3%

* Refer to the Specified Items schedules for further details.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO GAAP LINE ITEMS

FOR THE SIX MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, dollars in millions)

Six months ended June 30, 2013	GAAP		Specified Items*			Non GAAP
Gross Profit	$	5,708		155		$	5,863
Marketing, selling and administrative		2,036		(2	)		2,034
Research and development		1,881		—			1,881
Other (income)/expense		180		(258	)		(78	)
Effective Tax Rate		4.2%		8.3%			12.5%
Six months ended June 30, 2012	GAAP		Specified Items*			Non GAAP
Gross Profit	$	7,146		147		$	7,293
Marketing, selling and administrative		2,006		(13	)		1,993
Research and development		1,871		(103	)		1,768
Other (income)/expense		(235)		38			(197)
Effective Tax Rate		25.8%		0.3%			26.1%

* Refer to the Specified Items schedules for further details.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF NON-GAAP EPS TO GAAP EPS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2013 AND 2012

(Unaudited, amounts in millions except per share data)

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Net Earnings Attributable to BMS – GAAP	$	536	$	645	$	1,145	$	1,746
Earnings attributable to unvested restricted shares		—		—		—		(2	)
Net Earnings used for Diluted EPS Calculation – GAAP	$	536	$	645	$	1,145	$	1,744
Net Earnings Attributable to BMS – GAAP	$	536	$	645	$	1,145	$	1,746
Less Specified Items*		194		163		264		156
Net Earnings Attributable to BMS – Non-GAAP		730		808		1,409		1,902
Earnings attributable to unvested restricted shares		—		—		—		(2	)
Net Earnings used for Diluted EPS Calculation - Non-GAAP	$	730	$	808	$	1,409	$	1,900
Average Common Shares Outstanding - Diluted		1,660		1,701		1,658		1,704
Diluted EPS - GAAP	$	0.32	$	0.38	$	0.69	$	1.02
Diluted EPS Attributable to Specified Items		0.12		0.10		0.16		0.10
Diluted EPS - Non-GAAP	$	0.44	$	0.48	$	0.85	$	1.12

* Refer to the Specified Items schedules for further details.

BRISTOL-MYERS SQUIBB COMPANY

NET DEBT CALCULATION

AS OF JUNE 30, 2013 AND MARCH 31, 2013

(Unaudited, dollars in millions)

	June 30, 2013			March 31, 2013
Cash and cash equivalents	$	1,821		$	1,355
Marketable securities–current		978			1,178
Marketable securities–long-term		3,223			3,242
Cash, cash equivalents and marketable securities		6,022			5,775
Short-term borrowings and current portion of long-term debt		(764	)		(1,372	)
Long-term debt		(6,442	)		(6,522	)
Net debt position	$	(1,184	)	$	(2,119	)

EX-99.2

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

QUARTERLY TREND ANALYSIS OF SALES

($ in millions)

Net Sales	2012														2013										% Change		FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Total	$	5,251	$	4,443	$	9,694	$	3,736	$	13,430	$	4,191	$	17,621	$	3,831	$	4,048	$	7,879					(9)%	(19)%	(1)%	(1)%
US and Puerto Rico		3,501		2,629		6,130		2,016		8,146		2,238		10,384		1,971		2,045		4,016					(22)%	(34)%	—	—
Europe		922		926		1,848		858		2,706		1,000		3,706		946		950		1,896					3%	3%	1%	1%
Rest of the World		748		811		1,559		787		2,346		858		3,204		765		835		1,600					3%	3%	(5)%	(4)%
Other		80		77		157		75		232		95		327		149		218		367					**	**	—	—
% of Total Sales	2012														2013										Basis Point Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Total		100.0%		100.0%		100.0%		100.0%		100.0%		100.0%		100.0%		100.0%		100.0%		100.0%					—		—
US and Puerto Rico		66.7%		59.2%		63.2%		54.0%		60.7%		53.4%		58.9%		51.4%		50.5%		51.0%					(870)		(1,220)
Europe		17.6%		20.8%		19.1%		23.0%		20.1%		23.9%		21.0%		24.7%		23.5%		24.1%					270		500
Rest of the World		14.2%		18.3%		16.1%		21.0%		17.5%		20.5%		18.2%		20.0%		20.6%		20.3%					230		420
Other		1.5%		1.7%		1.6%		2.0%		1.7%		2.2%		1.9%		3.9%		5.4%		4.6%					370		300

** In excess of +/- 100%

1

BRISTOL-MYERS SQUIBB COMPANY

SALES AND COMPOSITION OF CHANGE IN SALES

FOR THE PERIOD ENDED JUNE 30, 2013

($ in millions)

QUARTER-TO-DATE	Net Sales				Analysis of % Change
	2013		2012		Total Change		Volume		Price		Foreign Exchange
US and Puerto Rico	$	2,045	$	2,629		(22)%		(21)%		(1)%		—
Europe		950		926		3%		6%		(4)%		1%
Rest of the World		835		811		3%		12%		(4)%		(5)%
Other		218		77		**		N/A		N/A		—
Total	$	4,048	$	4,443		(9)%		(6)%		(2)%		(1)%
YEAR-TO-DATE	Net Sales				Analysis of % Change
	2013		2012		Total Change		Volume		Price		Foreign Exchange
US and Puerto Rico	$	4,016	$	6,130		(34)%		(33)%		(1)%		—
Europe		1,896		1,848		3%		5%		(3)%		1%
Rest of the World		1,600		1,559		3%		10%		(3)%		(4)%
Other		367		157		**		N/A		N/A		—
Total	$	7,879	$	9,694		(19)%		(16)%		(2)%		(1)%

** In excess of +/- 100%

2

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS FROM OPERATIONS

($ in millions, except per share amounts)

	2012																					2013													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD
Net Sales	$	5,251		$	4,443		$	9,694		$	3,736		$	13,430		$	4,191		$	17,621		$	3,831		$	4,048		$	7,879						(9)%	(19)%
Cost of products sold		1,303			1,245			2,548			987			3,535			1,075			4,610			1,063			1,108			2,171						(11)%	(15)%
Marketing, selling and administrative		1,002			1,004			2,006			1,071			3,077			1,143			4,220			994			1,042			2,036						4%	1%
Advertising and product promotion		194			224			418			167			585			212			797			189			218			407						(3)%	(3)%
Research and development		909			962			1,871			951			2,822			1,082			3,904			930			951			1,881						(1)%	1%
Impairment charge for BMS-986094 intangible asset		—			—			—			1,830			1,830			—			1,830			—			—			—						—	—
Other (income)/expense		(184	)		(51	)		(235	)		(11	)		(246	)		166			(80	)		(19	)		199			180						**	**
Total Expenses		3,224			3,384			6,608			4,995			11,603			3,678			15,281			3,157			3,518			6,675						4%	1%
Earnings/(Loss) Before Income Taxes	$	2,027		$	1,059		$	3,086		$	(1,259	)	$	1,827		$	513		$	2,340		$	674		$	530		$	1,204						(50)%	(61)%
Provision for/(benefit from) income taxes		545			251			796			(546	)		250			(411	)		(161	)		51			—			51						(100)%	(94)%
Net Earnings/(Loss)	$	1,482		$	808		$	2,290		$	(713	)	$	1,577		$	924		$	2,501		$	623		$	530		$	1,153						(34)%	(50)%
Net Earnings/(Loss) Attributable to Noncontrolling Interest		381			163			544			(2	)		542			(1	)		541			14			(6	)		8						**	(99)%
Net Earnings/(Loss) Attributable to BMS	$	1,101		$	645		$	1,746		$	(711	)	$	1,035		$	925		$	1,960		$	609		$	536		$	1,145						(17)%	(34)%
Earnings attributable to unvested restricted shares		(1	)		—			(2	)		—			(1	)		(1	)		(1	)		—			—			—						—	(100)%
Net Earnings/(Loss) used for Diluted EPS Calculation	$	1,100		$	645		$	1,744		$	(711	)	$	1,034		$	924		$	1,959		$	609		$	536		$	1,145						(17)%	(34)%
Diluted Earnings/(Loss) per Common Share*	$	0.64		$	0.38		$	1.02		$	(0.43	)	$	0.61		$	0.56		$	1.16		$	0.37		$	0.32		$	0.69						(16)%	(32)%
Average Common Shares Outstanding - Diluted		1,706			1,701			1,704			1,666			1,697			1,662			1,688			1,655			1,660			1,658						(2)%	(3)%
Dividends declared per common share	$	0.34		$	0.34		$	0.68		$	0.34		$	1.02		$	0.35		$	1.37		$	0.35		$	0.35		$	0.70						3%	3%
% of Net Sales	2012																					2013													Basis Point Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD
Gross Margin		75.2%			72.0%			73.7%			73.6%			73.7%			74.3%			73.8%			72.3%			72.6%			72.4%						60	(130)
Cost of products sold		24.8%			28.0%			26.3%			26.4%			26.3%			25.7%			26.2%			27.7%			27.4%			27.6%						(60)	130
Marketing, selling and administrative		19.1%			22.6%			20.7%			28.7%			22.9%			27.3%			23.9%			25.9%			25.7%			25.8%						310	510
Advertising and product promotion		3.7%			5.0%			4.3%			4.5%			4.4%			5.1%			4.5%			4.9%			5.4%			5.2%						40	90
Research and development		17.3%			21.7%			19.3%			25.5%			21.0%			25.8%			22.2%			24.3%			23.5%			23.9%						180	460
Total expenses		61.4%			76.2%			68.2%			**			86.4%			87.8%			86.7%			82.4%			86.9%			84.7%						1,070	1,650
Earnings/ (Loss) Before Income Taxes		38.6%			23.8%			31.8%			(33.7)%			13.6%			12.2%			13.3%			17.6%			13.1%			15.3%						(1,070)	(1,650)
Net Earnings/ (Loss) Attributable to BMS		21.0%			14.5%			18.0%			(19.0)%			7.7%			22.1%			11.1%			15.9%			13.2%			14.5%						(130)	(350)
Other Ratios
Effective Tax Rate		26.9%			23.7%			25.8%			43.4%			13.7%			(80.1)%			(6.9)%			7.6%			—			4.2%						(2,370)	(2,160)
Other (Income)/Expense	2012																					2013													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD
Interest expense	$	42		$	41		$	83		$	48		$	131		$	51		$	182		$	50		$	50		$	100						22%	20%
Investment income		(36	)		(22	)		(58	)		(27	)		(85	)		(21	)		(106	)		(25	)		(28	)		(53	)					27%	(9)%
Provision for restructuring		22			20			42			29			71			103			174			33			173			206						**	**
Litigation charges/(recoveries)		(172	)		22			(150	)		50			(100	)		55			(45	)		—			(22	)		(22	)					**	(85)%
Equity in net income of affiliates		(57	)		(53	)		(110	)		(40	)		(150	)		(33	)		(183	)		(36	)		(50	)		(86	)					(6)%	(22)%
Out-licensed intangible asset impairment		38			—			38			—			38			—			38			—			—			—						—	(100)%
Gain on sale of product lines, businesses and assets		—			(3	)		(3	)		—			(3	)		(50	)		(53	)		(1	)		—			(1	)					(100)%	(67)%
Other income received from alliance partners, net		(46	)		(83	)		(129	)		(96	)		(225	)		(87	)		(312	)		(57	)		(32	)		(89	)					(61)%	(31)%
Pension settlements		—			—			—			3			3			155			158			—			101			101						—	—
Other		25			27			52			22			74			(7	)		67			17			7			24						(74)%	(54)%
	$	(184	)	$	(51	)	$	(235	)	$	(11	)	$	(246	)	$	166		$	(80	)	$	(19	)	$	199		$	180						**	**

* Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.

** In excess of +/- 100%

3

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

FOR THE PERIOD ENDED JUNE 3O, 2013

(Unaudited, amounts in millions except per share data)

QUARTER-TO-DATE

	2013		2012		Growth $			Growth %		Favorable / (Unfavorable) FX Impact $ *		2013 Excluding FX		Favorable / (Unfavorable) FX Impact % *		Growth % Excluding FX
Net sales	$	4,048	$	4,443		(395	)		(9)%	$	(42)	$	4,090		(1)%		(8)%
Gross profit		2,940		3,198		(258	)		(8)%		N/A		N/A		N/A		N/A
Gross profit excluding specified items (a)		3,010		3,345		(335	)		(10)%		N/A		N/A		N/A		N/A
Gross profit excluding specified items as a % of sales		74.4%		75.3%
Marketing, selling and administrative		1,042		1,004		38			4%		14		1,056		1%		5%
Marketing, selling and administrative excluding specified items (a)		1,041		999		42			4%		14		1,055		2%		6%
Advertising and product promotion		218		224		(6	)		(3)%		3		221		2%		(1)%
SG&A excluding specified items as a % of sales		31.1%		27.5%
Research and development		951		962		(11	)		(1)%		14		965		1%		—
Research and development excluding specified items (a)		951		917		34			4%		15		966		1%		5%
Research and development excluding specified items as a % of sales		23.5%		20.6%
YEAR-TO-DATE
	2013		2012		Growth $			Growth %		Favorable / (Unfavorable) FX Impact $ *		2013 Excluding FX		Favorable / (Unfavorable) FX Impact % *		Growth % Excluding FX
Net sales	$	7,879	$	9,694		(1,815	)		(19)%	$	(62)	$	7,941		(1)%		(18)%
Gross profit		5,708		7,146		(1,438	)		(20)%		N/A		N/A		N/A		N/A
Gross profit excluding specified items (a)		5,863		7,293		(1,430	)		(20)%		N/A		N/A		N/A		N/A
Gross profit excluding specified items as a % of sales		74.4%		75.2%
Marketing, selling and administrative		2,036		2,006		30			1%		25		2,061		2%		3%
Marketing, selling and administrative excluding specified items (a)		2,034		1,993		41			2%		25		2,059		1%		3%
Advertising and product promotion		407		418		(11	)		(3)%		4		411		1%		(2)%
SG&A excluding specified items as a % of sales		31.0%		24.9%
Research and development		1,881		1,871		10			1%		19		1,900		1%		2%
Research and development excluding specified items (a)		1,881		1,768		113			6%		21		1,902		2%		8%
Research and development excluding specified items as a % of sales		23.9%		18.2%

(a) Refer to the Specified Items tab for detail of specified items.

* Foreign exchange (FX) impact determined by the change in a line item’s current and prior period results at a common exchange rate and comparing this change to the actual reported change from the same period. This difference is determined to be the FX impact.

4

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

FOR THE PERIOD ENDED JUNE 30, 2013

(Unaudited, amounts in millions except per share data)

QUARTER-TO-DATE	2013		2012		Growth $			Growth %		Favorable / (Unfavorable) FX Impact $ *			2013 Excluding FX		Favorable / (Unfavorable) FX Impact % *		Growth % Excluding FX
Virology
Baraclude		371		357		14			4%		(10	)		381		(3)%		7%
Reyataz		431		406		25			6%		(5	)		436		(1)%		7%
Sustiva Franchise		411		388		23			6%		1			410		—		6%
Oncology
Erbitux		171		179		(8	)		(4)%		—			171		—		(4)%
Sprycel		312		244		68			28%		(10	)		322		(4)%		32%
Yervoy		233		162		71			44%		—			233		—		44%
Neuroscience
Abilify		563		711		(148	)		(21)%		2			561		—		(21)%
Metabolics
Bydureon		66		—		66			N/A		—			66		N/A		N/A
Byetta		104		—		104			N/A		—			104		N/A		N/A
Forxiga		5		—		5			N/A		—			5		N/A		N/A
Onglyza/Kombiglyze		240		172		68			40%		—			240		—		40%
Immunoscience
Nulojix		6		3		3			100%		—			6		—		100%
Orencia		352		290		62			21%		(7	)		359		(3)%		24%
Cardiovascular
Avapro/Avalide		56		117		(61	)		(52)%		—			56		—		(52)%
Eliquis		12		1		11			**		—			12		—		**
Plavix		44		741		(697	)		(94)%		—			44		—		(94)%
Mature Products and All Other		671		672		(1	)		—		(13	)		684		(2)%		2%
Total		4,048		4,443		(395	)		(9)%		(42	)		4,090		(1)%		(8)%
Total excluding Plavix and Avapro/Avalide		3,948		3,585		363			10%		(42	)		3,990		(1)%		11%

YEAR-TO-DATE	2013		2012		Growth $			Growth %		Favorable / (Unfavorable) FX Impact $*			2013 Excluding FX		Favorable / (Unfavorable) FX Impact % *		Growth % Excluding FX
Virology
Baraclude		737		682		55			8%		(15	)		752		(2)%		10%
Reyataz		792		764		28			4%		(6	)		798		—		4%
Sustiva Franchise		798		774		24			3%		2			796		—		3%
Oncology
Erbitux		333		358		(25	)		(7)%		—			333		—		(7)%
Sprycel		599		475		124			26%		(17	)		616		(4)%		30%
Yervoy		462		316		146			46%		2			460		—		46%
Neuroscience
Abilify		1,085		1,332		(247	)		(19)%		6			1,079		—		(19)%
Metabolics
Bydureon		118		—		118			N/A		—			118		N/A		N/A
Byetta		189		—		189			N/A		—			189		N/A		N/A
Forxiga		8		—		8			N/A		—			8		N/A		N/A
Onglyza/Kombiglyze		442		333		109			33%		(1	)		443		—		33%
Immunoscience
Nulojix		11		4		7			**		—			11		—		**
Orencia		672		544		128			24%		(11	)		683		(2)%		26%
Cardiovascular
Avapro/Avalide		102		324		(222	)		(69)%		—			102		—		(69)%
Eliquis		34		1		33			**		(2)			36		—		**
Plavix		135		2,434		(2,299	)		(94)%		—			135		—		(94)%
Mature Products and All Other		1,362		1,353		9			1%		(20	)		1,382		(1)%		2%
Total		7,879		9,694		(1,815	)		(19)%		(62	)		7,941		(1)%		(18)%
Total excluding Plavix and Avapro/Avalide		7,642		6,936		706			10%		(62	)		7,704		(1)%		11%

* Foreign exchange (FX) impact determined by the change in a line item’s current and prior period results at a common exchange rate and comparing this change to the actual reported change from the same period. This difference is determined to be the FX impact.

** In excess of +/- 100%

5

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE NET SALES FROM OPERATIONS BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2012														2013										% Change		FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs.YTD
TOTAL		5,251		4,443		9,694		3,736		13,430		4,191		17,621		3,831		4,048		7,879					(9)%	(19)%	(1)%	(1)%
Virology
Baraclude		325		357		682		346		1,028		360		1,388		366		371		737					4%	8%	(3)%	(2)%
Reyataz		358		406		764		363		1,127		394		1,521		361		431		792					6%	4%	(1)%	—
Sustiva Franchise (a)		386		388		774		370		1,144		383		1,527		387		411		798					6%	3%	—	—
Oncology
Erbitux		179		179		358		173		531		171		702		162		171		333					(4)%	(7)%	—	—
Sprycel		231		244		475		263		738		281		1,019		287		312		599					28%	26%	(4)%	(4)%
Yervoy		154		162		316		179		495		211		706		229		233		462					44%	46%	—	—
Neuroscience
Abilify (b)		621		711		1,332		676		2,008		819		2,827		522		563		1,085					(21)%	(19)%	—	—
Metabolics
Bydureon		—		—		—		20		20		58		78		52		66		118					N/A	N/A	N/A	N/A
Byetta		—		—		—		55		55		94		149		85		104		189					N/A	N/A	N/A	N/A
Forxiga		—		—		—		—		—		—		—		3		5		8					N/A	N/A	N/A	N/A
Onglyza/Kombiglyze (c)		161		172		333		178		511		198		709		202		240		442					40%	33%	—	—
Immunoscience
Nulojix		1		3		4		3		7		4		11		5		6		11					100%	**	—	—
Orencia (d)		254		290		544		307		851		325		1,176		320		352		672					21%	24%	(3)%	(2)%
Cardiovascular
Avapro/Avalide		207		117		324		95		419		84		503		46		56		102					(52)%	(69)%	—	—
Eliquis		—		1		1		—		1		1		2		22		12		34					**	**	—	—
Plavix		1,693		741		2,434		64		2,498		49		2,547		91		44		135					(94)%	(94)%	—	—
Mature Products and All Other (e)		681		672		1,353		644		1,997		759		2,756		691		671		1,362					—	1%	(2)%	(1)%
	2012														2013										% Change		FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Net Sales by Therapeutic Area:
Virology		1,077		1,165		2,242		1,089		3,331		1,145		4,476		1,121		1,225		2,346					5%	5%	(1)%	(1)%
Oncology		679		707		1,386		728		2,114		777		2,891		772		814		1,586					15%	14%	(2)%	(2)%
Neuroscience		627		716		1,343		680		2,023		823		2,846		526		568		1,094					(21)%	(19)%	—	—
Metabolics		194		206		400		299		699		409		1,108		400		480		880					**	**	—	(1)%
Immunocience		255		292		547		311		858		329		1,187		325		358		683					23%	25%	(2)%	(2)%
Cardiovascular		1,991		958		2,949		243		3,192		223		3,415		243		193		436					(80)%	(85)%	—	—
Other Therapeutic Areas		428		399		827		386		1,213		485		1,698		444		410		854					3%	3%	(2)%	(2)%

** In excess of +/- 100%

(a) The Sustiva Franchise includes sales of Sustiva and revenue of bulk efavirenz included in the combination therapy, Atripla.

(b) Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

(c) Includes Kombiglyze sales of $60M and $116M for the three and six months ended June 30, 2013 and $36M and $72M for the three and six months ended June 30, 2012 respectively.

(d) Includes Orencia SubQ sales of $100M and $184M for the three and six months ended June 30, 2013 and $46M and $77M for the three and six months ended June 30, 2012 respectively.

(e) Represents all other products, including those which have lost their exclusivity in major markets, over the counter brands and royalty-related revenue. Includes Symlin sales of $22M and $38M for the three and six months ended June 30, 2013.

6

BRISTOL-MYERS SQUIBB COMPANY

DOMESTIC NET SALES FROM OPERATIONS BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2012														2013												% Change				% Change in U.S. Total Prescription*
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
TOTAL (a)		3,501		2,629		6,130		2,016		8,146		2,238		10,384		1,971		2,045			4,016							(22)%		(34)%
Virology
Baraclude		56		59		115		61		176		65		241		68		73			141							24%		23%		4%		5%
Reyataz		188		199		387		197		584		199		783		193		200			393							1%		2%		(6)%		(7)%
Sustiva Franchise (b)		254		259		513		250		763		253		1,016		251		275			526							6%		3%		(2)%		(3)%
Oncology
Erbitux		176		176		352		169		521		167		688		158		168			326							(5)%		(7)%		N/A		N/A
Sprycel		95		91		186		109		295		109		404		115		135			250							48%		34%		23%		20%
Yervoy (c)		117		122		239		123		362		141		503		159		140			299							15%		25%		N/A		N/A
Neuroscience
Abilify (d)		445		533		978		507		1,485		617		2,102		328		378			706							(29)%		(28)%		—		(1)%
Metabolics
Bydureon		—		—		—		20		20		55		75		52		57			109							N/A		N/A		N/A		N/A
Byetta		—		—		—		55		55		92		147		84		74			158							N/A		N/A		N/A		N/A
Onglyza/ Kombiglyze (e)		120		126		246		130		376		140		516		140		167			307							33%		25%		1%		4%
Immunoscience
Nulojix		1		2		3		3		6		3		9		4		4			8							100%		**		N/A		N/A
Orencia(f)		171		199		370		211		581		216		797		214		238			452							20%		22%		N/A		N/A
Cardiovascular
Avapro/Avalide		108		22		130		9		139		16		155		—		(9	)		(9	)						**		**		N/A		N/A
Eliquis		—		—		—		—		—		—		—		17		5			22							N/A		N/A		N/A		N/A
Plavix		1,648		713		2,361		43		2,404		20		2,424		66		18			84							(97)%		(96)%		N/A		N/A
Mature Products     and All     Other  (g)		122		128		250		129		379		145		524		122		122			244							(5)%		(2)%
Total excluding Plavix     and     Avapro/Avalide		1,745		1,894		3,639		1,964		5,603		2,202		7,805		1,905		2,036			3,941							7%		8%
	2012														2013												% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr				YTD vs. YTD
Net Sales by Therapeutic Area:
Virology		498		519		1,017		509		1,526		518		2,044		513		548			1,061							6%				4%
Oncology		412		414		826		423		1,249		438		1,687		451		457			908							10%				10%
Neuroscience		445		534		979		506		1,485		617		2,102		328		378			706							(29)%				(28)%
Metabolics		127		132		259		224		483		316		799		298		324			622							**				**
Immunoscience		172		201		373		214		587		219		806		217		243			460							21%				23%
Cardiovascular		1,784		766		2,550		79		2,629		61		2,690		108		36			144							(95)%				(94)%
Other Therapeutic Areas		63		63		126		61		187		69		256		56		59			115							(6)%				(9)%

* The estimated U.S. prescription change data provided throughout this report includes information only from the retail and mail order channels and does not reflect product demand within other channels such as hospitals, home health care, clinics, Federal facilities including Veterans Administration hospitals, and long-term care (excluding diabetes franchise products Onglyza, Kombiglyze, Byetta and Bydureon), among others. Erbitux, Yervoy and Nulojix, and the intravenous formulation of Orencia are parenterally administered products and do not have prescription-level data as these products are not dispensed through retail and mail order channels. The data is provided by Wolters Kluwer Health based on the Source Prescription Audit and IMS Health based on information from the Next-Generation Prescription Service version 2.0 of the National Prescription Audit. The data is a product of each respective service providers’ own recordkeeping and projection processes and therefore subject to the inherent limitations of estimates based on sampling and may include a margin of error.

** In excess of +/- 100%

(a) Domestic net sales include United States and Puerto Rico.

(b) The Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. The change in U.S. total prescriptions growth for the Sustiva Franchise includes both branded Sustiva and Atripla prescription units.

(c) Includes $25 million of net sales that were previously deferred until sufficient historical experience to estimate sales returns was developed. The following table provides a reconciliation of the net impact of reversal of previously deferred net sales.

	2013				2012				% Change
	2nd Qtr		6 Months		2nd Qtr		6 Months		Qtr vs. Qtr		YTD vs. YTD
Yervoy Net Sales As Reported		140		299		122		239		15%		25%
Reversal of deferred revenues, net		—		(25)		—		—		N/A		N/A
Yervoy Net Sales - Adjusted		140		274		122		239		15%		15%

(d) Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd. The following table provides a reconciliation of the impact for extending the term of the commercialization and manufacturing agreement.

	2013				2012				% Change
	2nd Qtr		6 Months		2nd Qtr		6 Months		Qtr vs. Qtr		YTD vs. YTD
Abilify Net Sales As Reported		378		706		533		978		(29)%		(28)%
Contractual share change from 51.5% to 34.3%		199		354		—		—		N/A		N/A
Abilify Net Sales - Adjusted		577		1,060		533		978		8%		8%

(e) Includes Kombiglyze sales of $52M and $99M for the three and six months ended June 30, 2013 and $36M and $72M for the three and six months ended June 30, 2012, respectively.

(f) Includes Orencia SubQ sales of $83M and $153M for the three and six months ended June 30, 2013 and $45M and $76M for the three and six months ended June 30, 2012, respectively.

(g) Represents all other products sold in the U.S., including those which have lost their exclusivity in major markets. Includes Symlin sales of $22M and $38M for the three and six months ended June 30, 2013.

7

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL NET SALES FROM OPERATIONS BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2012														2013										% Change				FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
TOTAL		1,750		1,814		3,564		1,720		5,284		1,953		7,237		1,860		2,003		3,863						10%		8%		(3)%		(2)%
Virology
Baraclude		269		298		567		285		852		295		1,147		298		298		596						—		5%		(3)%		(3)%
Reyataz		170		207		377		166		543		195		738		168		231		399						12%		6%		(2)%		(2)%
Sustiva Franchise (a)		132		129		261		120		381		130		511		136		136		272						5%		4%		—		—
Oncology
Erbitux		3		3		6		4		10		4		14		4		3		7						—		17%		—		—
Sprycel		136		153		289		154		443		172		615		172		177		349						16%		21%		(7)%		(5)%
Yervoy		37		40		77		56		133		70		203		70		93		163						**		**		—		—
Neuroscience
Abilify (b)		176		178		354		169		523		202		725		194		185		379						4%		7%		—		—
Metabolics
Bydureon		—		—		—		—		—		3		3		—		9		9						N/A		N/A		N/A		N/A
Byetta		—		—		—		—		—		2		2		1		30		31						N/A		N/A		N/A		N/A
Forxiga		—		—		—		—		—		—		—		3		5		8						N/A		N/A		N/A		N/A
Onglyza/Kombiglyze		41		46		87		48		135		58		193		62		73		135						59%		55%		—		(2)%
Immunoscience
Nulojix		—		1		1		—		1		1		2		1		2		3						100%		**		—		—
Orencia		83		91		174		96		270		109		379		106		114		220						25%		26%		(8)%		(7)%
Cardiovascular
Avapro/Avalide		99		95		194		86		280		68		348		46		65		111						(32)%		(43)%		—		—
Eliquis		—		1		1		—		1		1		2		5		7		12						**		**		—		—
Plavix		45		28		73		21		94		29		123		25		26		51						(7)%		(30)%		—		—
Mature Products and All Other (c)		559		544		1,103		515		1,618		614		2,232		569		549		1,118						1%		1%		(2)%		(2)%
	2012														2013										% Change				FX Impact
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
Net Sales by Therapeutic Area:
Virology		579		646		1,225		580		1,805		627		2,432		608		677		1,285						5%		5%		(2)%		(2)%
Oncology		267		293		560		305		865		339		1,204		321		357		678						22%		21%		(5)%		(5)%
Neuroscience		182		182		364		174		538		206		744		198		190		388						4%		7%		1%		1%
Metabolics		67		74		141		75		216		93		309		102		156		258						**		83%		—		(1)%
Immunoscience		83		91		174		97		271		110		381		108		115		223						26%		28%		(8)%		(6)%
Cardiovascular		207		192		399		164		563		162		725		135		157		292						(18)%		(27)%		—		—
Other Therapeutic Areas		365		336		701		325		1,026		416		1,442		388		351		739						4%		5%		(3)%		(2)%

** In excess of +/- 100%

(a) The Sustiva Franchise includes sales of Sustiva and revenue of bulk efavirenz included in the combination therapy, Atripla.

(b) Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

(c) Represents all other products, including those which have lost their exclusivity in major markets, over the counter brands and royalty-related revenue.

8

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN NON-GAAP LINE ITEMS TO CERTAIN GAAP LINE ITEMS

(Unaudited, amounts in millions except per share data)

	2012														2013
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year
Gross Profit	$	3,948	$	3,198	$	7,146	$	2,749	$	9,895	$	3,116	$	13,011	$	2,768	$	2,940	$	5,708
Specified items (a)		—		147		147		54		201		84		285		85		70		155
Gross profit excluding specified items		3,948		3,345		7,293		2,803		10,096		3,200		13,296		2,853		3,010		5,863
Marketing, selling and administrative		1,002		1,004		2,006		1,071		3,077		1,143		4,220		994		1,042		2,036
Specified items (a)		(8)		(5)		(13)		(70)		(83)		(2)		(85)		(1)		(1)		(2)
Marketing, selling and administrative excluding specified items		994		999		1,993		1,001		2,994		1,141		4,135		993		1,041		2,034
Research and development		909		962		1,871		951		2,822		1,082		3,904		930		951		1,881
Specified items (a)		(58)		(45)		(103)		(48)		(151)		(65)		(216)		—		—		—
Research and development excluding specified items		851		917		1,768		903		2,671		1,017		3,688		930		951		1,881
Other (income)/expense		(184)		(51)		(235)		(11)		(246)		166		(80)		(19)		199		180
Specified items (a)		81		(43)		38		(116)		(78)		(249)		(327)		(19)		(239)		(258)
Other (income)/expense excluding specified items		(103)		(94)		(197)		(127)		(324)		(83)		(407)		(38)		(40)		(78)
Effective Tax Rate		26.9%		23.7%		25.8%		43.4%		13.7%		(80.1)%		(6.9)%		7.6%		—		4.2%
Specified items (a)		(0.2)%		1.6%		0.3%		(22.9)%		11.3%		95.1%		30.1%		3.4%		13.8%		8.3%
Effective Tax Rate excluding specified items		26.7%		25.3%		26.1%		20.5%		25.0%		15.0%		23.2%		11.0%		13.8%		12.5%

(a) Refer to the Specified Items tab for detail of specified items.

9

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

($ in millions)

	2012																					2013
Dollars in Millions	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year
Accelerated depreciation, asset impairment and other shutdown costs	$	—		$	147		$	147		$	—		$	147		$	—		$	147		$	—		$	—		$	—
Amortization of acquired Amylin intangible assets		—			—			—			91			91			138			229			138			137			275
Amortization of Amylin collaboration proceeds		—			—			—			(46	)		(46	)		(68	)		(114	)		(67	)		(67	)		(134	)
Amortization of Amylin inventory adjustment		—			—			—			9			9			14			23			14			—			14
Cost of products sold		—			147			147			54			201			84			285			85			70			155
Stock compensation from accelerated vesting of Amylin awards		—			—			—			67			67			—			67			—			—			—
Process standardization implementation costs		8			5			13			3			16			2			18			1			1			2
Marketing, selling and administrative		8			5			13			70			83			2			85			1			1			2
Stock compensation from accelerated vesting of Amylin awards		—			—			—			27			27			—			27			—			—			—
Upfront, milestone and other licensing payments		—			—			—			21			21			26			47			—			—			—
IPRD impairment		58			45			103			—			103			39			142			—			—			—
Research and development		58			45			103			48			151			65			216			—			—			—
Impairment charge for BMS-986094 intangible asset		—			—			—			1,830			1,830			—			1,830			—			—			—
Provision for restructuring		22			20			42			29			71			103			174			33			173			206
Gain on sale of product lines, businesses and assets		—			—			—			—			—			(51	)		(51	)		—			—			—
Acquisition and collaboration related items		12			1			13			29			42			1			43			—			(10	)		(10	)
Litigation charges/(recoveries)		(172	)		22			(150	)		50			(100	)		55			(45	)		—			(23	)		(23	)
Out-licensed intangible asset impairment		38			—			38			—			38			—			38			—			—			—
Loss on debt repurchase		19			—			19			8			27			—			27			—			—			—
Upfront, milestone and other licensing receipts		—			—			—			—			—			(10	)		(10	)		(14	)		—			(14	)
Pension settlements		—			—			—			—			—			151			151			—			99			99
Other (income)/expense		(81	)		43			(38	)		116			78			249			327			19			239			258
Increase/(decrease) to pretax income		(15	)		240			225			2,118			2,343			400			2,743			105			310			415
(Income tax)/tax benefit on items above		8			(77	)		(69	)		(722	)		(791	)		(156	)		(947	)		(35	)		(116	)		(151	)
Specified tax benefit*		—			—			—			—			—			(392	)		(392	)		—			—			—
(Income tax)/tax benefit		8			(77	)		(69	)		(722	)		(791	)		(548	)		(1,339	)		(35	)		(116	)		(151	)
Increase/(decrease) to net earnings	$	(7	)	$	163		$	156		$	1,396		$	1,552		$	(148	)	$	1,404		$	70		$	194		$	264

* The 2012 specified tax benefit relates to a capital loss deduction.

10

BRISTOL-MYERS SQUIBB COMPANY

SELECTED BALANCE SHEET INFORMATION

($ in millions)

	March 31, 2012		June 30, 2012		September 30, 2012			December 31, 2012			March 31, 2013			June 30, 2013			September 30, 2013	December 31, 2013
Cash and cash equivalents	$	2,307	$	2,801	$	1,503		$	1,656		$	1,355		$	1,821
Marketable securities - current		2,722		2,236		1,427			1,173			1,178			978
Marketable securities - long term		3,585		3,732		3,698			3,523			3,242			3,223
Cash, cash equivalents and marketable securities		8,614		8,769		6,628			6,352			5,775			6,022
Short-term borrowings and current portion of long-term debt		145		236		751			826			1,372			764
Long-term debt		5,270		5,209		6,608			6,568			6,522			6,442
Net cash/(debt) position	$	3,199	$	3,324	$	(731	)	$	(1,042	)	$	(2,119	)	$	(1,184	)

11

BRISTOL-MYERS SQUIBB COMPANY

2013 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS

EXCLUDING PROJECTED SPECIFIED ITEMS

	Full Year 2013
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP	$	1.41 to $1.49
Projected Specified Items:
Downsizing and streamlining of worldwide operations		0.10
Upfront and milestone payments, net		0.02
Amortization of Amylin intangible assets and collaboration proceeds		0.11
Pension settlements		0.08
Other		(0.02	)
Total		0.29
Projected Diluted Earnings Attributable to Shareholders per Common Share - Non-GAAP	$	1.70 to $1.78

Gross margin as a percentage of sales on a GAAP and non-GAAP basis for the six months ended June 30, 2013 was 72.4% and 74.4%, respectively. On a non-GAAP basis, the Company projects gross margin as a percentage of sales for the full year 2013 of approximately 73%. There is no reliable comparable GAAP measure for this forward-looking information on gross margin. See “—Reconciliation of GAAP and NON-GAAP Growth Dollars and Percentages Excluding Foreign Exchange Impact”.

Research and development expenses on a GAAP and non-GAAP basis for the six months ended June 30, 2013 were $1.9 billion. On a non-GAAP basis, the Company projects research and development expense for the full year 2013 to grow in the low single digit range compared to 2012. It is estimated that 30% to 40% of the research and development expenses in 2013 will be incurred on late-stage development programs. There is no reliable comparable GAAP measure for this forward-looking information on research and development. See “—Reconciliation of Certain NON-GAAP Line Items to Certain GAAP Line Items”.

Marketing, selling and administrative expenses, on a GAAP and non-GAAP basis for the six months ended June 30, 2013 were $2.0 billion. On a GAAP basis, expenses for the six months ended June 30, 2013 included specified items of $2 million. On a non-GAAP basis, the Company projects marketing, selling and administrative expenses for the full year 2013 to remain flat compared to 2012. There is no reliable comparable GAAP measure for this forward-looking information on marketing, selling and administrative expense. See “—Reconciliation of Certain NON-GAAP Line Items to Certain GAAP Line Items”.

The effective tax rate on a GAAP basis for the six months ended June 30, 2013 was 4.2%. On a non-GAAP basis, for the six months ended June 30, 2013 the effective tax rate was 12.5%. On a non-GAAP basis, the Company projects an annual effective tax rate of approximately 15%. There is no reliable comparable GAAP measure for this forward-looking information on the tax rate. See “—Reconciliation of Certain NON-GAAP Line Items to Certain GAAP Line Items”.

The GAAP financial results for the full year 2013 will include specified items, including expected charges associated with downsizing and streamlining worldwide operations, impairment charges, milestone payments, net amortization of acquired intangible assets and deferred income related to Amylin and pension settlements. The GAAP financial results for the full year 2013 could also include other specified items that have not yet been identified and quantified, including any gains or losses from acquisitions or divestitures, additional upfront, milestone and other licensing payments, charges for in-process research and development and licensed asset impairments, charges and recoveries relating to significant legal proceedings, restructuring activities and significant tax events. For a fuller discussion of certain litigation and other matters that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports Second Quarter 2013 Financial Results, July 25, 2013 including “2013 Financial Guidance” and “Use of Non-GAAP Financial Information” therein.

12